<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00109161</url>
  </required_header>
  <id_info>
    <org_study_id>DAC-1012</org_study_id>
    <nct_id>NCT00109161</nct_id>
  </id_info>
  <brief_title>Study of Subcutaneous Daclizumab in Patients With Active, Relapsing Forms of Multiple Sclerosis</brief_title>
  <official_title>A Phase II Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study of Subcutaneous Daclizumab in Patients With Active, Relapsing Forms of Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PDL BioPharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Facet Biotech</source>
  <brief_summary>
    <textblock>
      This research study is being conducted in the U.S. and Europe to evaluate the safety and
      efficacy of daclizumab for the treatment of multiple sclerosis (MS).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PDL BioPharma, Inc. was formerly known as Protein Design Labs, Inc.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2005</start_date>
  <completion_date>October 2006</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of new or enlarged gadolinium contrast enhancing lesions (Gd-CELs) on monthly brain MRIs collected between Weeks 8 to 24 in daclizumab- vs. placebo-treated patients</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical improvement</measure>
  </secondary_outcome>
  <enrollment>270</enrollment>
  <condition>Multiple Sclerosis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daclizumab (Anti-CD25 Humanized Monoclonal Antibody)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female age 18 to 55 years, inclusive.

          -  Diagnosis of MS by McDonald criteria.

          -  EDSS &lt;7.0.

          -  On stable IFN-beta regimen for at least 6 months.

          -  The occurrence of either of the following within 9 months prior to screening: ≥1 MS
             relapse OR A qualifying MRI, defined as an MRI that showed at least one confirmed
             Gd-CEL of the brain or spinal cord, was performed independently of the study while the
             patient was on a stable IFN-beta regimen, and is deemed acceptable by the central
             reader.

          -  For females, women of non-childbearing potential or women of childbearing potential
             who provide a negative serum pregnancy test at screen and within 24 hours of first
             dose of study drug, and who agree to use effective contraception during the Treatment
             and Follow-up periods of the study.

          -  Willing and able to comply with the protocol, provision of informed consent in
             accordance with institutional and regulatory guidelines, and, for US sites only,
             authorization to use protected health information.

        Exclusion Criteria:

          -  Pregnant or breast-feeding woman.

          -  Non-ambulatory patient.

          -  Clinically significant abnormality on screening ECG.

          -  Malignancy within the past 5 years, except for adequately treated non-melanoma skin
             carcinoma or in situ carcinoma of the cervix.

          -  History of HIV infection, positive serology for HBV (hepatitis B virus) or HCV
             (hepatitis C virus).

          -  Varicella (VZV) or herpes zoster virus infection, or any severe viral infection,
             within 6 weeks before screening or exposure to VZV within 21 days of screening.

          -  Abnormal hematology, as defined by the following laboratory values: *Hemoglobin ≤8.5
             g/dL, *Lymphocytes ≤1.0 x 10^9/L, *Platelets ≤100 x 10^9/L, *Neutrophils ≤1.5 x
             10^9/L.

          -  Significant organ dysfunction, including but not limited to cardiac, renal, liver,
             non-MS related CNS, pulmonary, vascular, gastrointestinal, endocrine, or metabolic
             dysfunction, or other disease or condition, which in the opinion of the PI (principal
             investigator) would make the patient an unsuitable candidate for the study. Guidelines
             for levels of unacceptable dysfunction include: *creatinine ≥1.6 mg/dL; *AST and ALT
             ≥2.5 times upper limit of normal (ULN); *alkaline phosphatase ≥2.5 times ULN; *history
             of myocardial infarction, congestive heart failure, or arrhythmias within 6 months
             prior to randomization.

          -  Use of any of the following: *Any of the following types of live virus vaccine from 4
             weeks before randomization: measles/mumps/rubella vaccine, varicella zoster virus
             vaccine, oral polio vaccine, and nasal influenza vaccine. Use of these vaccines,
             however, by household contacts does not affect the eligibility of patients to enroll
             or continue in the study; *Systemic corticosteroids, adrenocorticotropic hormone, or
             plasma exchange within 4 weeks before the baseline MRI scan (no more than 72 hours
             before Day 0); *Azathioprine, mycophenolate mofetil, methotrexate, glatiramer acetate,
             or intravenous immune globulin within 6 months before randomization; *An
             immunomodulatory agent within 6 months before randomization, except for
             interferon-beta products required per protocol; *An investigational agent within 6
             months before randomization unless this agent is non-immunomodulatory and the medical
             monitor or steering committee rules that its use is acceptable on the theoretical
             basis of a lapse of at least 5 serum half-lives since administration of the last
             possible dose; *A monoclonal antibody (eg, Rituxan®/ Rituximab) within 6 months before
             randomization; *Daclizumab at any time prior to randomization; *Cladribine,
             mitoxantrone, cyclophosphamide, CamPath® (alemtuzumab), natalizumab
             (TYSABRI®/Antegren) or other drugs targeting alpha 4 integrin, total lymphoid
             irradiation, or bone marrow transplant at any time

          -  Patients for whom MRI is contraindicated, ie, have pacemakers or other contraindicated
             implanted metal devices, are allergic to gadolinium, or have claustrophobia that
             cannot be medically managed.

          -  Primary progressive MS.

          -  Clinically unstable for 30 days before randomization (Patients who experienced a
             relapse, with or without steroid treatment, during the screening period may be
             re-screened after 30 days.)

          -  Elective surgery performed from 2 weeks prior to randomization or scheduled through
             Week 44

          -  Infection (viral, fungal, bacterial) requiring hospitalization or IV antibiotics
             within 8 weeks before randomization.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Dickson, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wenatchee Valley Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Steven Pugh, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rockwood Clinic, PS</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Daniel Wynn, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Consultants in Neurology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Theodore J. Phillips, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The MS Center at Texas Neurology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joanna Cooper</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sutter East Bay Medical Foundation</affiliation>
  </overall_official>
  <overall_official>
    <last_name>James R. Storey</last_name>
    <role>Principal Investigator</role>
    <affiliation>Upstate Clinical Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Malcolm Gottesman, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Winthrop University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Herman Sullivan, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Michigan Medical P.C. Neurology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Timothy Vollmer, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Joseph's Hospital and Medical Center, Phoenix</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jeffery Dunn, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>MS Hub Medical Group</affiliation>
  </overall_official>
  <overall_official>
    <last_name>S. Mitchell Freedman, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Raleigh Neurology Associates</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joseph Herbert, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital for Joint Diseases, MS Care Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Omar Khan, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wayne State University MS Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marcelo Kremenchutzky, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>London Health Sciences Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sharon Lynch, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>CLMC Neurology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alireza Minagar, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Louisiana State University Health Sciences Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jeffrey English, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Multiple Sclerosis Center of Atlanta</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrew Goodman, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Rochester</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Kaufman, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>MS Center/CMC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Florian P. Thomas, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Louis University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Clyde Markowitz, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jayne Martin, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Michigan State University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maria Melanson, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Health Sciences Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>MaryAnn Picone, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gimble MS Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christopher Bever, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maryland Center for MS</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gregg G. Blevins, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alberta</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kasper Lloyd, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>MS Center at Dartmouth</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yves Lapierrre, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Montreal Neurological Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John W. Rose, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Utah CAMT</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Yeung, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Foothills Medical Centre</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Neil Lava, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Albany Medical College</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jonathan L. Carter, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francois Jacques, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinique SEP/NM</affiliation>
  </overall_official>
  <overall_official>
    <last_name>William Honeycutt, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Neurology Associates, P.A.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Istvan Pirko, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cincinnati</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ed Fox, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Central Texas Neurology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Joseph's Hospital and Medical Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sutter East Bay Medical Foundation</name>
      <address>
        <city>Berkeley</city>
        <state>California</state>
        <zip>94705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurology Associates, P.A.</name>
      <address>
        <city>Maitland</city>
        <state>Florida</state>
        <zip>32751</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Multiple Sclerosis Center of Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30327</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consultants in Neurology</name>
      <address>
        <city>Northbrook</city>
        <state>Illinois</state>
        <zip>60062</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KUMC Neurology</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Louisiana State University Health Sciences Center</name>
      <address>
        <city>Shreveport,</city>
        <state>Louisiana</state>
        <zip>71103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maryland Center for MS</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wayne State University MS Center</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michigan State University</name>
      <address>
        <city>East Lansing</city>
        <state>Michigan</state>
        <zip>48824</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michigan Medical P.C. Neurology</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49525</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Louis University Hospital</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MS Center at Dartmouth</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gimble MS Center</name>
      <address>
        <city>Teaneck</city>
        <state>New Jersey</state>
        <zip>07666</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Upstate Clinical Research</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albany Medical Center</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Winthrop University Hospital</name>
      <address>
        <city>Mineola</city>
        <state>New York</state>
        <zip>11501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital for Joint Diseases, MS Care Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MS Center/CMC Meyers Park</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Raleigh Neurology Associates</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The MS Center at Texas Neurology</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Texas Neurology</name>
      <address>
        <city>Round Rock</city>
        <state>Texas</state>
        <zip>78681</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah CAMT</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MS Hub Medical Group</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rockwood Clinic, PS</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wenatchee Valley Medical Center</name>
      <address>
        <city>Wenatchee</city>
        <state>Washington</state>
        <zip>98801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Foothills Medical Centre-MS Research Program</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 2T9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Alberta</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G-2C8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Sciences Center</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3A 1R9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique SEP/NM</name>
      <address>
        <city>Gatineau</city>
        <state>Quebec</state>
        <zip>PQ J8Y 1W7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montreal Neurological Institute</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3A 2B4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.pdl.com</url>
  </link>
  <verification_date>August 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 22, 2005</study_first_submitted>
  <study_first_submitted_qc>April 22, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2005</study_first_posted>
  <last_update_submitted>August 2, 2008</last_update_submitted>
  <last_update_submitted_qc>August 2, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 5, 2008</last_update_posted>
  <keyword>Multiple Sclerosis, MS, CNS, Daclizumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Daclizumab</mesh_term>
    <mesh_term>Immunoglobulin G</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

